InvestLog
OKUR OnKure Therapeutics, Inc. logo

OKUR OnKure Therapeutics, Inc.

Healthcare
$4.21+3.44%ClosedMarket Cap: $57.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.31

P/S

0.00

EV/EBITDA

2.30

DCF Value

$4.23

FCF Yield

-88.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-61.0%

ROA

-29.6%

ROIC

-33.3%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-15.2M$—
Q4 null$0.00$-13.5M$—
FY null$0.00$-59.5M$—
Q3 null$0.00$-14.7M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$35.00

Target (Median)

$35.00

Target Range

$35.00 - $35.00

0 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-03-16
HC Wainwright & Co.Buy
2025-08-26

Trading Activity

Insider Trades

View All
AI Biotechnology LLC10 percent owner
SellTue Apr 07
AI Biotechnology LLC10 percent owner
SellTue Apr 07
Saccomano Nicholas Adirector, officer: President and CEO
SellFri Apr 03
Leverone Jason A.officer: Chief Financial Officer
SellFri Apr 03
Hartley Dylanofficer: Chief Scientific Officer
SellFri Apr 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.36

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

Peers

ALGS logoALGSATNM logoATNMBRNS logoBRNSCVM logoCVMFGEN logoFGENKZR logoKZRMRSN logoMRSNPDSB logoPDSBTPST logoTPSTXLO logoXLO